Acucela Doses First Subject in Phase I Trial for Age-Related Macular Degeneration
News Jun 04, 2008
Acucela Inc. has announced that it has dosed the first subject in a Phase I trial for its lead compound ACU-02. The single-site trial is enrolling healthy normal volunteers in a double-masked, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of ACU-02.
ACU-02 is an orally available small molecule being developed for the treatment of the dry form of age-related macular degeneration (AMD).
ACU-02 is a potent modulator of the visual cycle that acts by interrupting the pathophysiology of AMD by significantly reducing the accumulation of the retinal related toxic by-product A2E which is believed to damage retinal cells, thus leading to the decrease or loss of vision in AMD patients.
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE